KV9.2 inhibitors are a class of chemical compounds that specifically target and modulate the activity of KV9.2 channels, which are a subtype of voltage-gated potassium channels. These channels are part of the KV family, which plays a crucial role in controlling the flow of potassium ions across cell membranes. KV9.2 channels belong to the group of electrically silent modulatory subunits that do not form functional channels by themselves. Instead, they co-assemble with other potassium channel subunits, particularly KV2.x channels, to modulate their activity. The inhibition of KV9.2 subunits alters the overall gating properties and ion conductance of the heteromeric channel complex, thus impacting the regulation of membrane potential and ion homeostasis in excitable cells. KV9.2 channels are particularly involved in fine-tuning the excitability of neurons and other electrically active cells.
Chemically, KV9.2 inhibitors are diverse and can exhibit a wide range of molecular structures, including small molecules, peptides, or other complex organic compounds. Their specificity lies in their ability to selectively interact with the KV9.2 subunit within the heteromeric potassium channel complexes, often by altering the conformational dynamics of the pore-forming regions or by stabilizing inactive states. This inhibition can affect the overall conductance properties of the channel complex, leading to changes in the rate and duration of potassium ion flux during action potentials. By modulating the kinetics and dynamics of KV9.2-containing channels, these inhibitors are valuable tools for studying the intricate roles of potassium channels in cellular signaling, ion homeostasis, and the regulation of electrical properties in various cell types, particularly in neural and cardiac tissues. Their design and application in research allow for a deeper understanding of ion channel regulation and their broader physiological functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This compound intercalates into DNA, hindering the elongation phase of RNA synthesis by RNA polymerase, which would result in decreased transcription of the KCNS2 gene encoding KV9.2. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin specifically targets RNA polymerase II, potentially leading to decreased transcription and subsequent lower levels of KV9.2 mRNA. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to the mTOR complex and inhibits its activity, which can downregulate protein synthesis machinery, likely resulting in reduced synthesis of the KV9.2 protein. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By incorporating into DNA and RNA, 5-Azacytidine could cause hypomethylation of the KCNS2 gene's promoter region, potentially leading to downregulated transcription of KV9.2. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide can inhibit the transcription of multiple genes by mechanisms that are not fully understood but could involve interference with transcription factors, possibly leading to lower expression of KV9.2. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
This compound disrupts the transport of proteins from the endoplasmic reticulum to the Golgi apparatus, which could lead to impaired processing and trafficking of the KV9.2 channel to the plasma membrane. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 inhibits the ubiquitin-proteasome pathway, potentially leading to an increase in misfolded or improperly assembled KV9.2 channels that are targeted for degradation, effectively decreasing functional channel expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine raises the pH in endosomal and lysosomal compartments, which could disrupt the post-translational modification and trafficking of the KV9.2 protein, leading to decreased functional expression on the cell surface. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide blocks the translocation step in protein synthesis on ribosomes, which would directly lead to decreased synthesis of the KV9.2 protein. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA polymerase II by blocking the phosphorylation of the C-terminal domain of the enzyme, which could specifically result in the reduced transcription of the KV9.2 gene. | ||||||